AU2013291925B2 - Test kit for the quantitative determination of narcotic drugs - Google Patents

Test kit for the quantitative determination of narcotic drugs Download PDF

Info

Publication number
AU2013291925B2
AU2013291925B2 AU2013291925A AU2013291925A AU2013291925B2 AU 2013291925 B2 AU2013291925 B2 AU 2013291925B2 AU 2013291925 A AU2013291925 A AU 2013291925A AU 2013291925 A AU2013291925 A AU 2013291925A AU 2013291925 B2 AU2013291925 B2 AU 2013291925B2
Authority
AU
Australia
Prior art keywords
test kit
mmol
vessel
isotopologue
narcotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013291925A
Other languages
English (en)
Other versions
AU2013291925A1 (en
Inventor
Jon Eigill Johansen
Morten Salihi Karlsen
Huiling Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiron AS
Original Assignee
Chiron AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron AS filed Critical Chiron AS
Publication of AU2013291925A1 publication Critical patent/AU2013291925A1/en
Application granted granted Critical
Publication of AU2013291925B2 publication Critical patent/AU2013291925B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2013291925A 2012-07-19 2013-07-19 Test kit for the quantitative determination of narcotic drugs Active AU2013291925B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12177125.7A EP2687854A1 (en) 2012-07-19 2012-07-19 Test kit for the quantitative determination of narcotic drugs
EP12177125.7 2012-07-19
PCT/EP2013/065323 WO2014013063A1 (en) 2012-07-19 2013-07-19 Test kit for the quantitative determination of narcotic drugs

Publications (2)

Publication Number Publication Date
AU2013291925A1 AU2013291925A1 (en) 2015-02-05
AU2013291925B2 true AU2013291925B2 (en) 2018-11-29

Family

ID=48953365

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013291925A Active AU2013291925B2 (en) 2012-07-19 2013-07-19 Test kit for the quantitative determination of narcotic drugs

Country Status (5)

Country Link
US (1) US9347961B2 (en11)
EP (2) EP2687854A1 (en11)
AU (1) AU2013291925B2 (en11)
CA (1) CA2878670C (en11)
WO (1) WO2014013063A1 (en11)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI663400B (zh) 2017-09-28 2019-06-21 國立臺灣大學 檢測試紙及檢測毒品的方法
CN108535381A (zh) * 2018-04-12 2018-09-14 公安部物证鉴定中心 一种新精神活性物质2c-b-bzp的检测方法
CN108760908A (zh) * 2018-04-12 2018-11-06 公安部物证鉴定中心 一种新精神活性物质mbzp的检测方法
EP3864418A1 (en) * 2018-10-08 2021-08-18 Applied Photophysics Limited System and method for analysing the composition of a quenched flow reaction liquid
JP2022547567A (ja) * 2019-09-09 2022-11-14 ケア ケミカル テクノロジーズ インコーポレイテッド カンナビノイド誘導体、前駆体、および使用
CN113774412A (zh) * 2020-05-20 2021-12-10 深圳有为技术控股集团有限公司 异氰酸酯的电化学脱氢氧化制备方法
CN112500359B (zh) * 2020-12-18 2022-06-03 华中药业股份有限公司 一种劳拉西泮中间体的制备方法
CN113072509B (zh) * 2021-03-01 2022-11-25 中国科学院成都有机化学有限公司 一种合成7-氨基氯硝西泮化合物的方法
WO2022218382A1 (zh) * 2021-04-14 2022-10-20 成都百裕制药股份有限公司 氘代苯酚衍生物及其制备方法和用途
CN113549078A (zh) * 2021-08-05 2021-10-26 谱同生物医药科技(常州)有限公司 一种稳定同位素标记阿普唑仑、艾司唑仑内标试剂的制法
CA3230380A1 (en) 2021-09-01 2023-03-09 Nicholas MORRA Synthesis of mdma or its optically active (r)- or (s)-mdma isomers
CN113816914B (zh) * 2021-09-28 2024-04-09 华中药业股份有限公司 一种劳拉西泮中间体的制备方法
CN113773266A (zh) * 2021-09-28 2021-12-10 公安部物证鉴定中心 氯硝西泮-d2及其制备方法
US11845736B2 (en) 2021-10-01 2023-12-19 Empathbio, Inc. Prodrugs of MDMA, MDA, and derivatives thereof
EP4419886A1 (en) * 2021-10-19 2024-08-28 Dubai Police General Headquarters A composition, method and kit for extracting a narcotic compound from a biological sample
CN116023342B (zh) * 2021-10-26 2024-06-25 江苏昱林生物科技有限公司 一种高纯度氯硝西泮的制备方法
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CN116217641A (zh) * 2023-03-01 2023-06-06 上海原思标物科技有限公司 吗啡-D3-6-β-D-葡萄糖醛酸苷的合成方法及其中间体化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510700A (ja) 2002-12-20 2006-03-30 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ 同位体標識カンプトテシン誘導体
WO2006091885A2 (en) 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
AT501629B1 (de) 2005-04-05 2007-10-15 Erber Ag Herstellung von hochgradig isotopenmarkierten, sekundären, mikrobiellen stoffwechselprodukten sowie stoffwechselprodukte
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
JP2009502961A (ja) * 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US20070276001A1 (en) * 2005-09-14 2007-11-29 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US7514068B2 (en) * 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
US20080058351A1 (en) * 2006-06-30 2008-03-06 Concert Pharmaceuticals Inc. Novel heterobicyclic compounds
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
US8796267B2 (en) * 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
JP2008266149A (ja) 2007-04-17 2008-11-06 Tokyo Gas Chemicals Co Ltd １３ｃ標識ベンゼンの製造方法及び１３ｃ標識ベンゼン誘導体
WO2010065362A1 (en) 2008-11-25 2010-06-10 Innovative Technologies, L.L.C. Improvements in polypeptide synthesis for drug delivery
US20120156139A1 (en) * 2009-08-31 2012-06-21 Rachel Katz-Brull Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders
JP2011170533A (ja) 2010-02-17 2011-09-01 Glory Ltd 紙幣処理装置および収納庫
EP2551675A1 (en) 2011-07-28 2013-01-30 Chiron AS Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods fo their preparation and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERG T. et al., JOURNAL OF CHROMATOGRAPHY. (2011) vol. 1218, no. 52, pages 9366-9374. *
CHANG W.T. et al., "13C4-Secobarbital as the Internal Standard for the Quantitative Determination of Secobarbital-A Critical Evaluation", JOURNAL OF FORENSIC SCIENCES. (2000), vol. 45, no. 3, pages 659-664. *
LIU R.H. et al., "Peer Reviewed: Isotopically Labeled Analogues for Drug Quantitation", ANALYTICAL CHEMISTRY. (2002), vol. 74, no. 23, pages 618 A-626A. *

Also Published As

Publication number Publication date
EP2687854A1 (en) 2014-01-22
EP2875362A1 (en) 2015-05-27
US20150204893A1 (en) 2015-07-23
US9347961B2 (en) 2016-05-24
CA2878670A1 (en) 2014-01-23
CA2878670C (en) 2020-11-10
AU2013291925A1 (en) 2015-02-05
WO2014013063A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
AU2013291925B2 (en) Test kit for the quantitative determination of narcotic drugs
Desrosiers et al. Oral fluid drug testing: analytical approaches, issues and interpretation of results
Hubbard et al. Determination of dopamine, serotonin, and their metabolites in pediatric cerebrospinal fluid by isocratic high performance liquid chromatography coupled with electrochemical detection
Ghannay et al. Design, synthesis, molecular properties and in vitro antioxidant and antibacterial potential of novel enantiopure isoxazolidine derivatives
Stivala et al. Synthesis and biology of cyclic imine toxins, an emerging class of potent, globally distributed marine toxins
Huard et al. Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)
JP2023116823A (ja) 診断及び療法のための二環式化合物
EP2416795B1 (en) Inhibitors of cognitive decline
Huang et al. Bilirubin neurotoxicity is associated with proteasome inhibition
EA019252B1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
CN102595884B (zh) 认知衰退的抑制剂
JP6789578B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
Carpenter et al. Direct and systemic administration of a CNS-permeant tamoxifen analog reduces amphetamine-induced dopamine release and reinforcing effects
WO2017160156A1 (en) Synthetic capasaicin analogs as trpv1 agonists
Wiergowski et al. Determination of MDPBP in postmortem blood samples by gas chromatography coupled with mass spectrometry
Desharnais et al. A case of fatal idiosyncratic reaction to the designer drug 3, 4-methylenedioxypyrovalerone (MDPV) and review of the literature
CN103458885B (zh) 由姜黄油分离的化合物及使用方法
JP5986635B2 (ja) ５，６，７，８−テトラヒドロ−６−［ｎ，ｎ−ビス［（２−チエニル）エチル］］アミノ−１−ナフトール、及びその作製方法、及びその使用
AU2012288743B2 (en) Deuterium free, stable isotope labeled 2-phenylethylamine hallucinogens and/or stimulants, methods of their preparation and their use
Sigfridsson et al. Early development evaluation of AZD8081: a substrate for the NK receptors
Brandt N-Ethylnorpentylone. Critical Review Report.
US12338231B1 (en) N-heterocycle substituted tryptamine derivatives and methods of using
Minard Understanding the mode of action of TRPC1/4/5 ion channel modulators
Smith et al. Investigations of amination reactions on an antimalarial 1, 2, 4-triazolo [4, 3-a] pyrazine scaffold
Gentry et al. Development and characterization of a highly selective M5 PAM probe molecule with improved potency

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)